[18F]FDG-PET-CT for early monitoring of tumor response: When and why

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 2, 2009, Pages 167-180

  Storto, G ^a   Nicolai, E ^b   Salvatore, M ^c  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b IRCCS SDN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Fluorodeoxyglucose F18; Neoplasms, therapy; Positron emission tomography

Indexed keywords

CETUXIMAB; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; DIAGNOSTIC AGENT;

BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; ESOPHAGUS CANCER; HEAD AND NECK CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MONITORING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; STOMACH CANCER; TISSUE CHARACTERIZATION; TREATMENT RESPONSE; METABOLISM; METHODOLOGY; NEOPLASM; TREATMENT OUTCOME;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 69449099691     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
2. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
3. Fleming TR, Prentice RL, Pepe MS and Gidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 1994;13:955-68.
4. Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 2001;120:1584-91.
5. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:752-60.
6. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-6.
7. Heinrich S, Schäfer M, Weber A, Hany TF, Bhure U, Pestalozzi BC et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248:1014-22.
8. Bacci G, Ferrari S, Bertoni F, Picci P, Bacchini P, Longhi A et al. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop Relat Res 2001;386:186-96.
9. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 2004;100:1365-73.
10. Horiuchi C, Taguchi T, Yoshida T, Nishimura G, Kawakami M, Tanigaki Y et al. Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-d-glucose positron emission tomography. Auris Nasus Larynx. 2008;35:103-8.
11. Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-9.
12. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285-92.
13. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-60.
14. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179-87.
15. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-8. (Pubitemid 126447124)
16. Burcombe RJ, Makris A, Pittam M, Lowe J, Emmott J, Wong WL. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002;38:375-9.
17. Kim SJ, Kim SK, Lee ES, Ro J, Kang S. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-7.
18. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11. (Pubitemid 23332245)
19. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004;22:2167-71.
20. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979.
21. Miller AB, Hogestraeten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
22. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Mudal A et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-8. (Pubitemid 29157060)
23. Graf W, Pahlman L, Bergström R and Glimelius B, The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer, Br J Cancer 1994;70:559-63. (Pubitemid 24268565)
24. Lavin P, Mittelman A, Douglass H, Engström P, Klaassen D, Survival and response to chemotherapy for advanced colorectal adenocarcinoma, Cancer 1980;46:1536-43.
25. Anderson JR, Cain KC and Gelber RD. Analysis of survival by tumor response, J Clin Oncol 1983;1:710-9.
26. Sörenson S, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol. 2001;40:327-39.
27. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1-22.
28. Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282-308.
29. Weiss GB, Bunce III H, Hokanson JA, Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. Control Clin Trials 1983;4:43-52. (Pubitemid 13065044)
30. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA et al. on behalf of the European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Measurement of Clinical and Subclinical Tumor Response Using [18F]-fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations Eur J Cancer 1999;35:1773-82.
31. Zasadny KR, Wahl RL. Standardised uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose:variations with body weight and a method for correction. Radiology 1993;189:847-50.
32. Kim CK, Gupta NC. Dependency of standardised uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 1996;17:890-4.
33. Lammertsma AA, Brooks DJ, Frackowiak RSJ, Beaney RP, Herold S, Heather JD et al. Measurement of glucose utilisation with [18F]-fluoro-2-deoxy-d-glucose:a comparison of different analytical methods. J Cereb Blood Flow Metab 1987;7:161-72.
34. Sugawara Y, Zasadny KR, Barton Grossman H, Isaac RF, Clarke MF, Wahl RL. Germ cell tumor: differentiation of viable tumor, mature teratoma and necrotic tissue with FDG PET and kinetic modelling. Radiology 1999;211:249-56. (Pubitemid 29161760)
35. Brock CS, Young H, O'Reilly SM, Matthews J, Osman S, Evans H et al. Early evaluation of tumor metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608-15. (Pubitemid 30085198)
36. Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:331-8.
37. Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma (HNSCC). Head Neck 2002;24:127-35.
38. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144-50. (Pubitemid 43741076)
39. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362-70.
40. Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8.
41. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008;14:2012-8.
42. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005 20;23:7445-53.
43. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 2002;12:615-26.
44. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: is it useful? J Neurol Neurosurg Psychiatry. 1995;58:250-2.
45. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for reevaluation of positron emission tomography? AJNR 1998;19:407-13.
46. De Witte O, Hildebrand J, Luxen A, Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 1994;74:2836-42.
47. O'Reilly SM, Newlands ES, Harte RJA. Early changes in tumor glucose metabolism may predict and quantify response of gliomas to chemotherapy: a phase II study using temozolomide. Proc Am Soc Clin Oncol 1995;14:499.
48. Holthoff VA, Herholz K, Berthold F, Widemann B, Schröder R, Neubauer I et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993;72:1394-403.
49. Reisser C, Haberkorn U, Dimitrakopoulou-Strauss A, Seifert E, Strauss LG. Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg 1995;121:272-6.
50. Berlangieri SU, Brizel DM, Sher RL, Schifter T, Hawk TC, Hamblen S et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 1994;16:340-6. (Pubitemid 24188555)
51. Brun E, Ohlsson T, Erlandsson K, Kjellén E, Sandell A, Tennvall J et al. Early prediction of treatment outcome in head and neck cancer with 2-18FDG FDG PET. Acta Oncol. 1997;36:741-7. (Pubitemid 28078935)
52. Haberkorn U, Strauss L, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Ziegler S et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34:12-7. (Pubitemid 23014214)
53. Dalsaso TA, Lowe VJ, Dunphy FR, Martin DS, Boyd JH, Stack BC. FDG PET and CT in evaluation of chemotherapy in advanced head and neck cancer. Clin Positron Imaging 2000;3:1-5.
54. Greven KM, Williams DW, Keyes JW Jr, McGuirt WF, Watson NE Jr, Randall ME et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 1994;74:1355-9.
55. Rege S, Safa AA, Chaiken L, Hoh C, Juillard G, Withers HR. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol 2000;23:164-9.
56. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000;41:85-92. (Pubitemid 30046688)
57. Kunkel M, Forster GJ, Reichert TE, Kutzner J, Benz P, Bartenstein P et al. Radiation response non-invasively imaged by [18F]FDG PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol 2003;39:170-7.
58. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Onco. 2000;18:1676-88.
59. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-95
60. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-14. (Pubitemid 39663314)
61. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008;26:4449-57.
62. Gennari A, Donati S, Salvadori B, Giorgetti A, Salvadori PA, Sorace O et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156-61.
63. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7.
64. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:463-71.
65. de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007;48:1592-8.
66. Nahmias C, Hanna WT, Wahl LM, Long MJ, Hubner KF, Townsend DW. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 2007;48:744-51.
67. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85:1403-6.
68. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65. (Pubitemid 32565444)
69. Nakamura R, Obara T, Katsuragawa S. Failure in presumption of residual disease by quantification of FDG uptake in esophageal squamous cell carcinoma immediately after RT. Radiat Med 2002;20:181-6.
70. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-10.
71. Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C et al. The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 2007;10:221-7.
72. Shinto A, Nair N, Dutt A, Baghel NS. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Clin Nucl Med 2008;33:486-7.
73. Guillem JG, Puig-La CJ Jr, Akhurst T, Tickoo S, Ruo L, Minsky BD et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000;43:18-24.
74. Amthauer H, Denecke T, Rau B, Hildebrandt B, Hünerbein M, Ruf J et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 2004;31:811-9. (Pubitemid 38758350)
75. Calvo FA, Domper M, Matute R, Martínez-Lázaro R, Arranz JA, Desco M et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004;58:528-35.
76. Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20:4453-8.
77. Joosten J, Jager G, Oyen W, Wobbes T, Ruers T. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol 2005;31:1152-9.
78. Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007;11:472-8.
79. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700-8.
80. Bender H, Bangard N, Metten N, Bangard M, Mezger J, Schomburg A et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999;18:87-91. (Pubitemid 29140427)
81. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003;47:8-1.3
82. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Rühl A, Irngartinger G, Stremmel W et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004;45:1480-7.
83. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008;19:348-52.
84. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G et al. Oncological applications of positron emission tomography with fluorine-18-fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74. (Pubitemid 127496268)
85. Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U, Ho AD et al. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie 2008;31:107-12.
86. Bouchelouche K, Oehr P. Recent developments in urologic oncology: positron emission tomography molecular imaging . Curr Opin Oncol 2008;20:321-6.
87. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005;43:189-204.
88. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F] FDG) after first-line chemotherapy in non- Hodgkin's lymphoma: is [18F]FDGPET a valid alternative to conventional diagnosis methods? J Clin Oncol 2001;19:414-9.
89. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-27.